dc.contributor.author |
Marais, Andre
|
|
dc.date.accessioned |
2016-09-09T07:16:40Z |
|
dc.date.available |
2016-09-09T07:16:40Z |
|
dc.date.issued |
2016 |
|
dc.description.abstract |
Erectile dysfunction (ED) is a trivial condition with a prevailing incidence worldwide. Phosphodiesterase-5 inhibitors (PDE-5) have
revolutionised the treatment of ED and are regarded as one of the most successful drug groups in modern medicine. Generally
PDE-5 inhibitors are well tolerated and the incidence of side-effects is low, however a small percentage of individuals experience
headache, flushing and abdominal discomfort, resulting in discontinuation of therapy. This has led to the development of
second generation PDE-5 inhibitors, displaying more selectivity for the PDE-5 enzyme thereby reducing treatment interruption
and improving compliance. Several other treatment modalities, including testosterone replacement therapy and prostaglandin
administration are available for resistant or failed first-line treatment. This review provides an update on the current, and future,
available drugs used in the management of ED. |
en_ZA |
dc.description.department |
Pharmacology |
en_ZA |
dc.description.librarian |
am2016 |
en_ZA |
dc.description.uri |
http://www.safpj.co.za/index.php/safpj |
en_ZA |
dc.description.uri |
http://www.tandfonline.com/oemd |
en_ZA |
dc.identifier.citation |
Marais, A 2016, 'The pharmacological management of erectile dysfunction – Update 2016', South African Family Practice, vol. 58, no. 4, pp. 10-14. |
en_ZA |
dc.identifier.issn |
2078-6190 (print) |
|
dc.identifier.issn |
2078-6204 (online) |
|
dc.identifier.uri |
http://hdl.handle.net/2263/56678 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
MedPharm Publications |
en_ZA |
dc.rights |
© 2016 The Author(s). Open Access article distributed under the terms of the
Creative Commons License [CC BY-NC-ND 4.0]
http://creativecommons.org/licenses/by-nc-nd/4.0. |
en_ZA |
dc.subject |
Cardiovascular disease |
en_ZA |
dc.subject |
Prostaglandin |
en_ZA |
dc.subject |
Testosterone |
en_ZA |
dc.subject |
Erectile dysfunction (ED) |
en_ZA |
dc.subject |
Phosphodiesterase-5 inhibitors (PDE-5) |
en_ZA |
dc.title |
The pharmacological management of erectile dysfunction – Update 2016 |
en_ZA |
dc.type |
Article |
en_ZA |